MedTrace Logo

Characteristics and Treatment Patterns of Patients With Chronic Obstructive Pulmonary Disease (COPD), Initiating Tio+Olo or Other Maintenance Therapies in the US and the UK: A Retrospective Claims Database Study

NCT04926233 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1371146

Last updated 2021-11-15

Study results available
· View outcomes & findings →

Summary

The primary objectives of the study are to use US and UK data to describe the characteristics of Chronic Obstructive Pulmonary Disease (COPD) patients according to various demographic, lifestyle, clinical, and medication use.

Conditions

  • Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

Tiotropium bromide + Olodaterol

Tiotropium bromide + Olodaterol

DEVICE

Sp(t)iolto® Respimat®

Sp(t)iolto® Respimat®

Sponsors & Collaborators

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-11-15
Primary Completion
2020-04-14
Completion
2020-04-14
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04926233 on ClinicalTrials.gov